WO2000021506A3 - Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy - Google Patents

Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy Download PDF

Info

Publication number
WO2000021506A3
WO2000021506A3 PCT/CA1999/000949 CA9900949W WO0021506A3 WO 2000021506 A3 WO2000021506 A3 WO 2000021506A3 CA 9900949 W CA9900949 W CA 9900949W WO 0021506 A3 WO0021506 A3 WO 0021506A3
Authority
WO
WIPO (PCT)
Prior art keywords
glutathione
arsenic
antimony
modulators
pharmaceutical composition
Prior art date
Application number
PCT/CA1999/000949
Other languages
French (fr)
Other versions
WO2000021506A2 (en
Inventor
Wilson Miller
Gerald Batist
Kelly Davison
Original Assignee
Univ Mcgill
Wilson Miller
Gerald Batist
Kelly Davison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill, Wilson Miller, Gerald Batist, Kelly Davison filed Critical Univ Mcgill
Priority to AU60746/99A priority Critical patent/AU6074699A/en
Publication of WO2000021506A2 publication Critical patent/WO2000021506A2/en
Publication of WO2000021506A3 publication Critical patent/WO2000021506A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to combination of glutathione modulators with antimony and/or arsenic for cancer therapy. More particularly, the present invention relates to a pharmaceutical composition for the treatment of cancer, which comprises a therapeutical amount of a glutathione (GSH) modulator with antimony and/or arsenic in association with a pharmaceutically acceptable carrier.
PCT/CA1999/000949 1998-10-13 1999-10-12 Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy WO2000021506A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60746/99A AU6074699A (en) 1998-10-13 1999-10-12 Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,250,631 1998-10-13
CA2250631 1998-10-13

Publications (2)

Publication Number Publication Date
WO2000021506A2 WO2000021506A2 (en) 2000-04-20
WO2000021506A3 true WO2000021506A3 (en) 2000-07-20

Family

ID=4162919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000949 WO2000021506A2 (en) 1998-10-13 1999-10-12 Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy

Country Status (2)

Country Link
AU (1) AU6074699A (en)
WO (1) WO2000021506A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002226382A (en) * 2001-01-31 2002-08-14 Gifu International Institute Of Biotechnology Therapeutic agent for cancer
WO2002096412A1 (en) 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same
EP1572070A4 (en) 2001-09-07 2009-11-04 Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
ES2629682T3 (en) 2004-03-29 2017-08-14 University Of South Florida Effective treatment of tumors and cancer with triciribin phosphate
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412211A1 (en) * 1982-09-17 1991-02-13 Therapeutical Systems Corporation Cancer therapy system
WO1996022791A1 (en) * 1995-01-13 1996-08-01 Octamer, Inc. Novel synergistic compositions useful as anti-tumor or anti-retroviral agents
WO1998008566A1 (en) * 1996-08-30 1998-03-05 Duke University Manipulations of nitrosative and oxidatives stress in the treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412211A1 (en) * 1982-09-17 1991-02-13 Therapeutical Systems Corporation Cancer therapy system
WO1996022791A1 (en) * 1995-01-13 1996-08-01 Octamer, Inc. Novel synergistic compositions useful as anti-tumor or anti-retroviral agents
WO1998008566A1 (en) * 1996-08-30 1998-03-05 Duke University Manipulations of nitrosative and oxidatives stress in the treatment of disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AKAO, YUKIHIRO ET AL: "Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro", FEBS LETTERS (1999), 455(1,2), 59-62, XP000891674 *
BUDAVARI ET AL (EDS): "The Merck Index", 1996, MERCK &CO INC, WHITEHOUSE STATION NJ, USA, XP002134919 *
CHEN, ZHE-SHENG ET AL: "Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (1997), 236(3), 586-590, XP000891680 *
DAI, JIE ET AL: "Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system", BLOOD (1999), 93(1), 268-277, XP000891685 *
DE BITTENCOURT, PAULO I. HOMEM, JR. ET AL: "Effects of the antiproliferative cyclopentenone prostaglandin A1 on glutathione metabolism in human cancer cells in culture", BIOCHEM. MOL. BIOL. INT. ( 1998 ), 45(6), 1255-1264, XP000901409 *
KIM, HO-SHIK ET AL: "Intracellular glutathione level modulates the induction of apoptosis by.DELTA.12-prostaglandin J2", PROSTAGLANDINS (1996), 51(6), 413-425, XP000891683 *
LEE, TE CHANG ET AL: "Resistance mechanism of an arsenic -resistant cell line", HO TZU K'O HSUEH (1989), 26(6), 488-96, XP002134918 *
OCHI, TAKAFUMI ET AL: "Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione", ARCH. TOXICOL. (1996), 70(12), 815-821, XP000901249 *
SHEN, ZHI-XIANG ET AL: "Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients", BLOOD (1997), 89(9), 3354-3360, XP000891715 *
SNYDER, RONALD D. ET AL: "Thiol involvement in the inhibition of DNA repair by metals in mammalian cells", MOL. TOXICOL. (1989), 2(2), 117-28, XP000901255 *

Also Published As

Publication number Publication date
AU6074699A (en) 2000-05-01
WO2000021506A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AU7031500A (en) Therapeutic quinazoline compounds
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
AU1107500A (en) Tooth path treatment plan
AP9801392A0 (en) Concentrated antibody preparation.
WO1999043355A3 (en) Formulations containing oxaliplatin
AU2002351753A1 (en) Combined use of a glp-1 compound and a modulator of diabetic late complications
WO2003039632A3 (en) A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
AU6754496A (en) Medicine comprising hgf gene
WO1996003151A3 (en) Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
BR9610386A (en) Use of a compound capable of antagonizing, at least partially, the oncogenic activity of the mdm2 protein, use of an scfv, directed against the 1-134 domain of the mdm2 protein, use of a nucleic acid encoded for a compound capable of antagonizing the oncogenic activity mdm2 protein, viral vector and pharmaceutical composition
AU4155897A (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
IL131229A (en) Compounds having enzymatic conversion inhibition for therapeutic intervention in preventing diabetic complications, pharmaceutical preparations and uses thereof
WO2000021506A3 (en) Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy
CA2280773A1 (en) Methods for the administration of amifostine
UA32457C2 (en) Drug (variants) and methods for exposure to drug
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
BR9814419A (en) "combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases"
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MXPA02005045A (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer.
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
AU1469097A (en) Pharmaceutical compounds
AU2003221096A1 (en) Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09807393

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase